AkandaSTU:Y232 21 EBITDA Margin % is -17,353.64% as of Dec. 2025. GuruFocus rates STU:Y232 with a GF Score™ of 21/100. The stock has 9 warning signs investors should review. Among 955 Drug Manufacturers companies, Akanda ranks worse than 99.27% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Akanda's EBITDA for the
six
months ended in Dec. 2025 was €-38.18 Mil. Akanda's Revenue for the
six
months ended in Dec. 2025 was €0.22 Mil. Therefore, Akanda's EBITDA margin for the quarter that ended in Dec. 2025 was -17,353.64%.
Akanda (STU:Y232) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Akanda EBITDA Margin % Related Terms
Akanda EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Akanda's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:Y232 vs BFRI, BIOE, CABR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akanda's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akanda EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akanda's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Akanda's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akanda (STU:Y232) has a EBITDA Margin % of -17,353.64% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Akanda and its competitors. According to the industry distribution chart, Akanda ranks #948 out of 955 companies in the Drug Manufacturers industry, placing it in the top 99.3%.
Is Akanda's EBITDA Margin % too high?
Akanda's current EBITDA Margin % is -17,353.64%. Based on the distribution chart, Akanda ranks #948 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Akanda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Akanda's EBITDA Margin % compare to BFRI and BIOE?
According to the Drug Manufacturers industry distribution chart, Akanda ranks #948 out of 955 companies for EBITDA Margin %. This places Akanda in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Akanda and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akanda's current EBITDA Margin % is -17,353.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akanda stock overvalued right now?
Akanda (STU:Y232) has a current EBITDA Margin % of -17,353.64%. The current EBITDA Margin % is -17,353.64%. Akanda's overall GF Score™ is 21/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Akanda (STU:Y232), the current EBITDA Margin % is -17,353.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company is a medical cannabis & hemp and wellness platform company seeking to help people lives through improved access to high-quality and affordable products. The Company is also in the business of leasing fiber optic networks and telecommunication towers, through its subsidiary. The company has four reportable segments: Infrastructure, Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Infrastructure segment, which relates to the leasing and/or rental of fiber optic networks and telecommunication towers at First Towers in Mexico.
21GF Score
Get the complete analysis for STU:Y232
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:Y232 has been successfully added to your 
